TG Therapeutics Highlights Seven-Year BRIUMVI Data, Positive Phase 3 ENHANCE Results and Progress in Progressive MS Research at MSToronto2026 TG Therapeutics, Inc. (NASDAQ: TGTX) has announced a series of updated clinical and real-world data presentations at MSToronto2026, the 10th Joint…
Bionyra Pharma Reports Positive Interim Phase 1 Results for Long-Acting Anti-TL1A Antibody BYN-002 Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics designed to harness multi-targeted biology for immune-mediated inflammatory diseases, has announced positive interim results from its ongoing Phase…
Parse Biosciences Launches Evercode MAX to Expand Single-Cell Sequencing Capacity and Reduce Research Costs Parse Biosciences, a leading provider of scalable and accessible single-cell sequencing technologies and a QIAGEN company, has announced that Evercode™ MAX, a modular configuration of its…
Orogen Therapeutics Selects ORO-110 and ORO-210 Development Candidates for Inflammatory Diseases Orogen Therapeutics, Inc. (“Orogen” or the “Company”) announced the selection of two development candidates, ORO-110 and ORO-210, as potential next-generation oral small-molecule treatments for a range of inflammatory and…
Curi Bio Expands Curiverse With New Disease Models, 3D Tissue Casting Kits and Advanced Drug Discovery Assays Curi Bio, a biotechnology company developing advanced human-relevant research tools for drug discovery, has announced a significant expansion of its Curiverse™ ecosystem. The…
Cure First to More Than Double PARIS Test Capacity, Expanding Functional Precision Medicine Access for Patients With Difficult-to-Treat Cancers Cure First, a Seattle-based 501(c)(3) nonprofit organization focused on expanding access to functional precision medicine for patients with difficult-to-treat cancers, has…
IgniteData and RealTime eClinical Solutions Partner to Streamline Clinical Trial Data Transfers Through Archer Platform IgniteData, a provider of intelligent clinical trial data automation technology, and RealTime eClinical Solutions, a developer of clinical research software, have announced a new partnership…
Tortugas Neuroscience Reports Positive Phase 2b Results for Obuprazine in Schizophrenia, Showing Significant Symptom Improvements and Rapid Clinical Response Tortugas Neuroscience, a clinical-stage biotechnology company focused on developing transformative therapies for central nervous system (CNS) disorders, has announced positive Phase…
Rubedo Life Sciences Reports Phase 1b Data Showing Reduced Skin Epigenetic Age and Inflammatory Biomarkers With RLS-1496 Rubedo Life Sciences, a clinical-stage biotechnology company developing therapeutics designed to rejuvenate cellular functions disrupted by aging, has announced new clinical findings for…
Bristol Myers Squibb Reports Positive Phase 3 ALOFT-IPF Results for Admilparant in Idiopathic Pulmonary Fibrosis Bristol Myers Squibb has announced topline results from its pivotal Phase 3 ALOFT-IPF clinical trial evaluating admilparant, an investigational oral lysophosphatidic acid receptor 1 (LPA1)…
Final MINT Study Results Highlight Real-World Benefits of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE: 4151), has announced the final results of the German MINT study,…
Affinia Therapeutics to Present AFTX-201 Preclinical Data and UPBEAT Trial Progress in BAG3-Associated Dilated Cardiomyopathy at HFSA 2026 Affinia Therapeutics, a clinical-stage gene therapy company developing potentially first-in-class and best-in-class adeno-associated virus (AAV) gene therapies for serious diseases, particularly cardiovascular…